Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific...

Area of Science:

• Oncology
• Virology
• Genomics

Background:

• Endemic Burkitt lymphoma (eBL) is a prevalent pediatric cancer in Africa, strongly associated with Epstein-Barr virus (EBV).
• Sporadic Burkitt lymphoma (sBL) presents differently and has lower incidence in developed nations.
• Understanding eBL pathogenesis requires detailed molecular comparison with sBL.

Purpose of the Study:

• To investigate transcriptomic and genomic differences between endemic Burkitt lymphoma (eBL) and sporadic Burkitt lymphoma (sBL).
• To identify molecular factors, particularly EBV's role, in eBL pathogenesis.
• To explore potential new biomarkers and therapeutic targets for Burkitt lymphoma.

Main Methods:

• RNA sequencing (RNAseq) was employed to analyze transcriptomes of primary eBL and sBL tumors.
• Surrogate variable analysis was used to detect gene expression differences.
• Genomic and mutational analyses were performed on tumor specimens.

Main Results:

• eBL tumors exhibited homogeneity regarding presentation site, survival, and EBV type.
• Decreased expression of immunoproteasome genes (PSMB9, PSMB10, PSMB8, PSME2) was observed in eBL with EBV type 2 compared to EBV type 1.
• PTEN/PI3K/mTOR pathway alterations were linked to EBV status, not geography, in eBL versus sBL.
• New candidate mutated genes (TFAP4, MSH6, PRRC2C, BCL7A, FOXO1, PLCG2, PRKDC, RAD50, RPRD2) were identified in Burkitt lymphoma.
• EBV type 1 was associated with fewer common mutations in eBL, suggesting a role in oncogenesis.

Conclusions:

• Epstein-Barr virus (EBV), particularly type 1, plays a significant role in driving Burkitt lymphoma oncogenesis.
• EBV's influence may reduce the necessity for specific host genetic mutations in eBL development.
• Findings suggest potential for novel prognostic biomarkers and therapeutic strategies based on EBV status and molecular pathways.